The Scorecard, published by the NHS Health and Social Care Information Centre (HSCIC), is designed to help patients better understand how well their local health services are providing NICE recommended medicines and technologies. This data shows that there is wide variation between the medicines patients can access in one part of England compared to other parts.
The ABPI has welcomed the Innovation Scorecard as it gives a greater understanding of the use NICE approved medicines at a local level than previously available and helps promote greater transparency to the way medicines are used in the NHS. It is hoped that by revealing the extent of variation in the availability of medicines, steps can be taken to ensure that patients who need a treatment can access it, no matter where they live in the country.
However there is recognition from the pharmaceutical industry that the publication is experimental in nature and many more new medicines need to be included in the Scorecard in future if it is to become a useful, long-term tool. Worryingly though, of the new medicines measured against expected uptake, their usage is much lower than expected. This again appears to demonstrate the on-going problems with getting the latest and most innovative medicines to NHS patients.
Commenting, Stephen Whitehead, Chief Executive of the ABPI, said:
“I am delighted that the Innovation Scorecard has now been published – it is a key component of the Government’s drive to improve the use of medicines in the UK and their Innovation, Health and Wealth agenda.
"This first Scorecard is less detailed than the ABPI hoped for and we envisage future scorecards offering more details on how the NHS is complying with NICE guidance. But we welcome its publication as a first step on a transparency journey in the new NHS. We have worked closely with the Department of Health, HSCIC and other stakeholders to develop the Scorecard and understand the limitations of data that currently exists in the system. We look forward to working in partnership with the NHSCB to develop the Scorecard in the future.
“The variations in the use of medicines across England that this report reveals, must spur us in to action so that in years to come patients can access the same medicines, no matter where they live. I believe the Government understands the challenges, but it must act quickly and decisively to drive the adoption and diffusion of the newest and most innovative medicines across England.”
ABPI Press Office
Tel: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441
Mobile: +44 (0) 7808 641810 or +44 (0) 7850 312064
Notes to Editor
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.